整合临床、影像与分子分析预测库欣病的缓解与复发
这项回顾性多中心研究纳入2004至2018年诊断的60例ACTH瘤患者,随访至少2年,评估临床/生化变量及肿瘤分子表达谱。肿瘤大小、诊断至手术时间、血清催乳素和术后皮质醇与缓解及复发相关,SSTR1、CRHR1和MKI67与复发和/或缓解相关。整合临床变量(肿瘤大小/术后血清皮质醇)与分子标志物(SSTR1/CRHR1)的模型可准确预测临床演变和缓解,ROC曲线下面积为1(P < .001)。
要点
- 肿瘤大小、诊断至手术时间、血清催乳素和术后皮质醇与ACTH瘤缓解及复发相关。
- SSTR1、CRHR1和MKI67在ACTH瘤中差异表达,与复发和/或缓解相关。
- 整合临床变量与分子标志物的模型预测缓解,ROC曲线下面积为1(P < .001)。
核心结论
- ACTH瘤中一组临床与分子标志物的组合能准确预测患者的临床演变和缓解。
- 术后分子表达谱是ACTH瘤患者临床评估和随访的有价值工具。
研究设计与样本
- 回顾性多中心研究,纳入2004至2018年诊断的60例ACTH瘤患者,随访至少2年。
- 每年评估临床/生化变量,首次手术后检测肿瘤样本中生长抑素/胃饥饿素/多巴胺调控系统组分及关键垂体因子和增殖标志物的分子表达谱。
主要发现
- 肿瘤大小、诊断至首次手术时间、血清催乳素和术后皮质醇水平等临床变量与肿瘤缓解和复发疾病相关。
- SSTR1、CRHR1和MKI67等分子标志物在ACTH瘤中差异表达,与复发和/或缓解存在提示性关联。
- 整合选定临床变量(肿瘤大小/术后血清皮质醇)与分子标志物(SSTR1/CRHR1)的模型可准确预测临床演变和缓解,ROC曲线下面积为1(P < .001)。
关键数值与推荐
- 整合模型(临床变量:肿瘤大小/术后血清皮质醇;分子标志物:SSTR1/CRHR1)预测ACTH瘤患者临床演变和缓解的ROC曲线下面积为1(P < .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Adrenocorticotropin (ACTH)-secreting pituitary tumors (ACTHomas) are associated with severe comorbidities and increased mortality. Current treatments mainly focus on remission and prevention of persistent disease and recurrence. However, there are still no useful biomarkers to accurately predict the clinical outcome after surgery, long-term remission, or disease relapse. OBJECTIVES: This work aimed to identify clinical, biochemical, and molecular markers for predicting long-term clinical outcome and remission in ACTHomas. METHODS: A retrospective multicenter study was performed with 60 ACTHomas patients diagnosed between 2004 and 2018 with at least 2 years' follow-up. Clinical/biochemical variables were evaluated yearly. Molecular expression profile of the somatostatin/ghrelin/dopamine regulatory systems components and of key pituitary factors and proliferation markers were evaluated in tumor samples after the first surgery. RESULTS: Clinical variables including tumor size, time until diagnosis/first surgery, serum prolactin, and postsurgery cortisol levels were associated with tumor remission and relapsed disease. The molecular markers analyzed were distinctly expressed in ACTHomas, with some components (ie, SSTR1, CRHR1, and MKI67) showing instructive associations with recurrence and/or remission. Notably, an integrative model including selected clinical variables (tumor size/postsurgery serum cortisol), and molecular markers (SSTR1/CRHR1) can accurately predict the clinical evolution and remission of patients with ACTHomas, generating a receiver operating characteristic curve with an area under the curve of 1 (P < .001). CONCLUSION: This study demonstrates that the combination of a set of clinical and molecular biomarkers in ACTHomas is able to accurately predict the clinical evolution and remission of patients. Consequently, the postsurgery molecular profile represents a valuable tool for clinical evaluation and follow-up of patients with ACTHomas.
引用
- Moreno-Moreno P, Ibáñez-Costa A, Venegas-Moreno E, et al. Integrative Clinical, Radiological, and Molecular Analysis for Predicting Remission and Recurrence of Cushing Disease. J Clin Endocrinol Metab. 2022. PMID: 35312002. doi:10.1210/clinem/dgac172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。